# Belarus Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Belarus HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Belarus (BLR) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $432.8M - Products: 33 - Buyer markets: 27 - Average CAGR: +8.4% - Global sector size: $502.4B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $305.0B | $139.4M | $114.7B | +4.5% | 21 | +0.1% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.2B | $9.0M | $19.7B | +19.6% | 13 | +0.1% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $9.3B | $11.6K | $11.3B | +51.0% | 2 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $19.8B | $90.3K | $9.1B | +6.6% | 6 | +0.0% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $22.1B | $493.7K | $8.5B | +1.4% | 3 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $12.8B | $32.8K | $8.3B | +8.5% | 3 | +0.0% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.5B | $47.5K | $7.7B | +25.7% | 4 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $6.6B | $338.6 | $6.2B | -24.2% | 2 | +0.0% | | HS 330300 - Perfumes and toilet waters | $8.5B | $168.4K | $5.0B | -1.2% | 3 | +0.0% | | HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $2.2K | $4.8B | +13.1% | 1 | +0.0% | | HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.8B | $265.0M | $4.6B | +6.9% | 2 | +3.7% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $9.3B | $316.4 | $4.4B | +17.4% | 2 | +0.0% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $7.9B | $78.4K | $4.1B | +2.8% | 3 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $5.8B | $13.8K | $3.6B | +15.9% | 2 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $3.9B | $17.7K | $3.4B | -0.9% | 2 | +0.0% | | HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $2.7K | $3.2B | -15.1% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $24.4 | $2.0B | -11.3% | 1 | +0.0% | | HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $163.7 | $2.0B | -15.2% | 1 | +0.0% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $54.1K | $1.9B | +81.6% | 1 | +0.0% | | HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $622.5K | $1.8B | +9.3% | 1 | +0.4% | | HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $402.7K | $1.7B | +1.4% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.3 | $1.4B | -4.9% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $12.1 | $1.4B | -14.5% | 1 | +0.0% | | HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $6.6M | $1.2B | +15.5% | 1 | +2.1% | | HS 281820 - Aluminium oxide: other than artificial corundum | $2.3B | $2.1K | $1.1B | +1.5% | 1 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.2B | $12.4K | $1.1B | +12.7% | 1 | +0.0% | | HS 310210 - Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | $2.0B | $10.7M | $1.0B | +49.0% | 1 | +0.4% | | HS 300220 - Vaccines: for human medicine | $1.5B | $99.4 | $1.0B | -28.6% | 1 | +0.0% | | HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $27.6K | $990.0M | +63.3% | 1 | +0.0% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $2.0B | $23.2 | $981.1M | -18.4% | 1 | +0.0% | | HS 280461 - Silicon: containing by weight not less than 99.99% of silicon | $839.5M | $7.5 | $927.8M | -38.9% | 1 | +0.0% | | HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $1.6B | $1.1 | $871.2M | -38.5% | 1 | +0.0% | | HS 300449 - Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, packaged for retail sale | $1.5B | $788.8 | $841.5M | +10.6% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $41.6B calculated opportunity across 11 products. - Germany (DEU): $30.6B calculated opportunity across 12 products. - Switzerland, Liechtenstein (CHE): $27.7B calculated opportunity across 1 products. - Slovenia (SVN): $20.3B calculated opportunity across 2 products. - Netherlands (NLD): $18.9B calculated opportunity across 6 products. - China (CHN): $17.7B calculated opportunity across 7 products. - Italy (ITA): $8.4B calculated opportunity across 3 products. - Canada (CAN): $8.3B calculated opportunity across 5 products. - Belgium (BEL): $7.9B calculated opportunity across 2 products. - Spain (ESP): $7.4B calculated opportunity across 3 products. - Brazil (BRA): $6.3B calculated opportunity across 4 products. - United Kingdom (GBR): $6.1B calculated opportunity across 2 products. ## Growth stars - HS 382319: +81.6% average CAGR, $1.9B calculated opportunity. - HS 294190: +63.3% average CAGR, $990.0M calculated opportunity. - HS 293399: +51.0% average CAGR, $11.3B calculated opportunity. - HS 310210: +49.0% average CAGR, $1.0B calculated opportunity. - HS 330499: +25.7% average CAGR, $7.7B calculated opportunity. - HS 382499: +19.6% average CAGR, $19.7B calculated opportunity. - HS 300212: +17.4% average CAGR, $4.4B calculated opportunity. - HS 300439: +15.9% average CAGR, $3.6B calculated opportunity. - HS 310221: +15.5% average CAGR, $1.2B calculated opportunity. - HS 293379: +13.1% average CAGR, $4.8B calculated opportunity. ## Diversification opportunities - HS 300490: 21 buyer markets, $114.7B calculated opportunity. - HS 382499: 13 buyer markets, $19.7B calculated opportunity. - HS 382200: 6 buyer markets, $9.1B calculated opportunity. - HS 330499: 4 buyer markets, $7.7B calculated opportunity. - HS 300215: 3 buyer markets, $8.5B calculated opportunity. - HS 293499: 3 buyer markets, $8.3B calculated opportunity. - HS 330300: 3 buyer markets, $5.0B calculated opportunity. - HS 381800: 3 buyer markets, $4.1B calculated opportunity. - HS 293399: 2 buyer markets, $11.3B calculated opportunity. - HS 300214: 2 buyer markets, $6.2B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.